Summary of evidence for the involvement of AUBPs in the pathophysiology of human leukemias and lymphomas
| AUBP . | Leukemia . | Targets . | References . |
|---|---|---|---|
| AUF1 (hnRNP D) | Colocalizes with NMP-ALK in ALCL, phosphorylated and inactivated | MYC,* cyclins A and D,* BCLXl, Bfl-1, JUN | 21 |
| HuR (ELAVL1) | Overexpressed in M4 AML and in CML blast crisis, colocalizes with NPM-ALK in ALCL and is phosphorylated, functions downstream of ATM | elF4E,* cEBPβ,* p21,* FOXO3,* MEK1,* MEK2,* DUSP10,* ZFP36L1,* MYC, p53, CD95L, XIAP, survivin, miR-7 | 38,42,44,45,48 |
| KHSRP (KSRP) | Not shown yet but possibly in AML, ALL, CLL, and MM | Let 7 family, miR-16, miR-15, miR-20, miR-106b, miR-26b, miR-155, etc | 50,–52 |
| Nucleolin | Overexpressed in CLL, AML, pediatric ALL, refractory and relapsed AML, and ALL | BCL2, BCLXl, CD40L, MYC | 55,70,71,72 |
| ZFP36 (Tis11) | Decreased in CML blast crisis, decreased in DLBCL, decrease in acute-phase ATL | Interaction and inhibition of Tax transactivation,* VEGF, several cytokines | 45,84,86,92,93 |
| ZFP36L1 (Tis11b) | Decreased in CLL, decreased in DLBCL, deleted in CLL and NHLs, mutated in MM | c-IAP-2, VEGF, several cytokines | 75,90,92,97 |
| ZFP36L2 (Tis11d) | Increased in AML, mutated in AML | Several cytokines | 96,98 |
| AUBP . | Leukemia . | Targets . | References . |
|---|---|---|---|
| AUF1 (hnRNP D) | Colocalizes with NMP-ALK in ALCL, phosphorylated and inactivated | MYC,* cyclins A and D,* BCLXl, Bfl-1, JUN | 21 |
| HuR (ELAVL1) | Overexpressed in M4 AML and in CML blast crisis, colocalizes with NPM-ALK in ALCL and is phosphorylated, functions downstream of ATM | elF4E,* cEBPβ,* p21,* FOXO3,* MEK1,* MEK2,* DUSP10,* ZFP36L1,* MYC, p53, CD95L, XIAP, survivin, miR-7 | 38,42,44,45,48 |
| KHSRP (KSRP) | Not shown yet but possibly in AML, ALL, CLL, and MM | Let 7 family, miR-16, miR-15, miR-20, miR-106b, miR-26b, miR-155, etc | 50,–52 |
| Nucleolin | Overexpressed in CLL, AML, pediatric ALL, refractory and relapsed AML, and ALL | BCL2, BCLXl, CD40L, MYC | 55,70,71,72 |
| ZFP36 (Tis11) | Decreased in CML blast crisis, decreased in DLBCL, decrease in acute-phase ATL | Interaction and inhibition of Tax transactivation,* VEGF, several cytokines | 45,84,86,92,93 |
| ZFP36L1 (Tis11b) | Decreased in CLL, decreased in DLBCL, deleted in CLL and NHLs, mutated in MM | c-IAP-2, VEGF, several cytokines | 75,90,92,97 |
| ZFP36L2 (Tis11d) | Increased in AML, mutated in AML | Several cytokines | 96,98 |
DLBCL indicates diffuse large B-cell lymphoma.
Gene targets that have been experimentally validated for their direct role in AUBP-mediated leukemogenesis.